Given the apparent beneficial effects of some TRP agonists and bile acids on whole-body substrate and energy metabolism, the TRP/TGR5–BAT axis represents a promising target for combating obesity and related metabolic disorders in humans. The gene discussed is GPBAR1; the disease is obesity due to melanocortin 4 receptor deficiency.